



Altimune to Participate at Two Upcoming Investor Conferences

November 22, 2022

GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences:

- **Evercore ISI 5th Annual HealthCONx Virtual Conference**
Tuesday, November 29, 2022
Fireside chat at 10:55 am Eastern Time
- **Piper Sandler 34th Annual Healthcare Conference in New York, NY**
Thursday, December 1, 2022
Fireside chat at 10:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Altimune Investor & Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com



Source: Altimune, Inc